Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia

L-DOPA administration is the primary treatment for Parkinson’s disease (PD) but long-term administration is usually accompanied by hyperkinetic side-effects called L-DOPA-induced dyskinesia (LID). Signaling neuropeptides of the basal ganglia are affected in LID and changes in the expression of neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hulme, Heather, Fridjonsdottir, Elva, Vallianatou, Theodosia, Shariatgorji, Reza, Nilsson, Anna, Li, Qin, Bezard, Erwan, Andrén, Per E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007979/
https://www.ncbi.nlm.nih.gov/pubmed/35418178
http://dx.doi.org/10.1038/s41531-022-00299-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007979/
https://www.ncbi.nlm.nih.gov/pubmed/35418178
http://dx.doi.org/10.1038/s41531-022-00299-7

Ejemplares similares